Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes
Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise expectations, but cost structure remains a risk.
Market read
First profitable quarter and raised guidance provide a fresh catalyst for CLOV, likely influencing short‑interest and institutional buying.
What to watch
High expense ratio (87.6%) and increasing overhead may limit profitability despite revenue growth.
Background
Clover Health is a Medicare Advantage insurer that has struggled to achieve profitability. The latest quarter shows a turning point.
Ticker impact
Clover Health reported Q2 2026 GAAP profit of $28M and raised full-year guidance, marking its first profitable quarter.
Potential price appreciation if the market prices in the new profitability and higher EBITDA outlook.
Profitability after a loss and a 48% membership surge provide a strong catalyst; guidance lift reinforces growth expectations.
Market effects
Signals strength in the Medicare Advantage sector, potentially boosting peers with similar risk‑adjusted models.
U.S. healthcare investors may re‑weight exposure to Medicare Advantage insurers.
Limited to U.S. markets; no direct global ripple.
Counterpoint
Rising medical claim costs and thin margins could pressure earnings if membership growth slows.
Key entities
- CEOAndrew Toy
CEO highlighted the Clover Assistant platform as a growth engine.
- Interim CFOClay Thornton
CFO linked improved cohort economics to the full‑risk model.
